Harmony Biosciences
HRMY
32.59
-0.39
-1.18%
Harmony Biosciences
US · HRMY
#2681 by market cap
Listed 2020
32.59
-0.39
-1.18%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
About Harmony Biosciences
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
- Founded
- 2017
- CEO
- Dr. Jeffrey M. Dayno, M.D.
- Employees
- 293
- Headquarters
- Plymouth Meeting, Pennsylvania, United States of America
- Fiscal year end
- 12-31
- Website
- harmonybiosciences.com
Company profile
- Exchange
- US
- Symbol
- HRMY
- Market-cap rank
- #2681
- Listing date
- 2020-08-19
- Market cap
- 1.91B
- Float cap
- 1.71B
- Shares out
- 58.72M
- Float shares
- 52.58M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-11-20 20:02:36 · For reference only, not investment advice and not tailored to your situation.
Harmony Biosciences discussion 0 comments